No connection

Search Results

TXMD

BEARISH
$2.18 Live
TherapeuticsMD, Inc. · NASDAQ
$0.98 52W Range $2.95
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 22, 2026
Market cap
$25.23M
P/E
N/A
ROE
-2.4%
Profit margin
-18.8%
Debt/Equity
0.23
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
TXMD exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational inefficiency. While the company shows strong top-line revenue growth of 33.9% and maintains a healthy current ratio of 3.02, these are offset by a disastrous operating margin of -108.51% and a 5-year price collapse of -96.5%. The stock is currently trading near its book value (P/B 0.94), but the lack of consistent profitability and a history of volatile earnings surprises make it a high-risk speculative play.

Key Strengths

Strong YoY revenue growth of 33.90%
Robust liquidity with a current ratio of 3.02
Low leverage with a Debt/Equity ratio of 0.23
Trading slightly below book value (P/B 0.94)
Significant short-term price recovery (+118% over 1 year)

Key Risks

Critically low Piotroski F-Score (2/9) signaling fundamental decay
Severe operational losses with an operating margin of -108.51%
Extreme long-term value destruction (-96.5% 5-year change)
Highly volatile earnings track record with frequent large misses
Micro-cap status ($0.03B) leading to high volatility and low liquidity
AI Fair Value Estimate
Based on comprehensive analysis
$2.1
-3.7% below current price

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
26
Weak
Value
45
Future
50
Past
15
Health
20
Dividend
0
AI Verdict
Speculative / High Risk
Key drivers: Piotroski F-Score, Operating Margin, 5-Year Price Trend, Revenue Growth
Confidence
90%
Value
45/100

Ref P/E, PEG, Graham Number

Positives
  • P/B ratio of 0.94 suggests the stock is priced near liquidation value
Watchpoints
  • High Price/Sales ratio (8.35) relative to negative profitability
  • No Graham Number available due to lack of positive earnings
Future
50/100

Ref Growth rates

Positives
  • Strong revenue growth (33.9%)
  • Low forward P/E (6.23) suggests projected profitability
Watchpoints
  • Year-over-year EPS growth is -101.9%
  • Inconsistent earnings surprise history
Past
15/100

Ref Historical trends

Positives
  • Recent 1-year recovery (+118%)
Watchpoints
  • Catastrophic 5-year performance (-96.5%)
  • Long history of quarterly losses
Health
20/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • Low Debt/Equity (0.23)
  • Strong Current Ratio (3.02)
Watchpoints
  • Piotroski F-Score of 2/9 is a major red flag for financial health
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend payments
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$2.18

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for TXMD and closest competitors.

Updated 2026-04-21
TXM
TherapeuticsMD, Inc.
Primary
5Y
-96.5%
3Y
-41.7%
1Y
+118.0%
6M
+86.3%
1M
-5.6%
1W
+3.3%
LFW
Lifeward Ltd.
Peer
5Y
-96.0%
3Y
-88.2%
1Y
-60.6%
6M
-26.0%
1M
-1.6%
1W
-4.2%
DAR
Daré Bioscience, Inc.
Peer
5Y
-91.0%
3Y
-85.0%
1Y
-38.6%
6M
-21.2%
1M
+15.7%
1W
-2.8%
ICC
IceCure Medical Ltd
Peer
5Y
-97.0%
3Y
-71.2%
1Y
-71.9%
6M
-62.9%
1M
-51.7%
1W
+7.7%
PLS
Pulsenmore Ltd.
Peer
5Y
-50.4%
3Y
-50.4%
1Y
-50.4%
6M
-50.4%
1M
-13.1%
1W
+9.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
6.23
PEG Ratio
N/A
P/B Ratio
0.94
P/S Ratio
8.35
EV/Revenue
7.89
EV/EBITDA
-12.03
Market Cap
$25.23M

Profitability

Profit margins and return metrics

Profit Margin -18.83%
Operating Margin -108.51%
Gross Margin 100.0%
ROE -2.41%
ROA -3.87%

Growth

Revenue and earnings growth rates

Revenue Growth +33.9%
Earnings Growth N/A
Q/Q Revenue Growth +33.88%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.23
Low debt
Current Ratio
3.02
Strong
Quick Ratio
2.44
Excellent
Cash/Share
$0.65

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Op. Margin
-167.5%
Net Margin
-69.3%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.40x
Operating CF
$0.0B
Free Cash Flow
$0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2023-08-14
$-0.24
-242.9% surprise
2023-05-15
$-0.24
-500.0% surprise
2023-04-07
$8.23
+841.4% surprise
2022-11-14
$-3.13
-53.4% surprise

Healthcare Sector Comparison

Comparing TXMD against 502 companies in the Healthcare sector (29 bullish, 154 neutral, 319 bearish)
Return on Equity (ROE)
-2.41%
This Stock
vs
-94.61%
Sector Avg
-97.5% (Below Avg)
Profit Margin
-18.83%
This Stock
vs
-15.81%
Sector Avg
+19.1% (Superior)
Debt to Equity
0.23
This Stock
vs
2.86
Sector Avg
-92.1% (Less Debt)
Revenue Growth
33.9%
This Stock
vs
136.45%
Sector Avg
-75.2% (Slower)
Current Ratio
3.02
This Stock
vs
4.65
Sector Avg
-35.1% (Weaker)

Similar Companies

Peer comparison within the same industry

TXMD TherapeuticsMD, Inc.
BEARISH
Mkt Cap
$25M
P/E
-
ROE
-2.4%
Price
$2.18
LFWD Lifeward Ltd.
BEARISH
Mkt Cap
$25M
P/E
-
ROE
-146.1%
Price
$6.57
 Compare with TXMD
DARE Daré Bioscience, Inc.
BEARISH
Mkt Cap
$26M
P/E
-
ROE
-%
Price
$1.77
 Compare with TXMD
ICCM IceCure Medical Ltd
BEARISH
Mkt Cap
$26M
P/E
-
ROE
-188.8%
Price
$0.32
 Compare with TXMD
PLSM Pulsenmore Ltd.
BEARISH
Mkt Cap
$24M
P/E
-
ROE
-17.6%
Price
$3.65
 Compare with TXMD

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

THOMPSON TOMMY G
Director
Buy
2025-12-23
8,400 shares · $14,031
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-K
ANNUAL REPORT
2026-03-30

TXMD filed its Annual Report (Form 10-K) on March 30, 2026. Due to the lack of detailed content in the provided excerpts, specific financial highlights and risk factors are unavailable.

8-K
CURRENT REPORT
2026-03-30

TXMD filed a current report on March 30, 2026, likely announcing its first-quarter financial results.

8-K
CURRENT REPORT
2026-01-21
8-K
CURRENT REPORT
2025-12-16
8-K
CURRENT REPORT
2025-11-13
10-Q
QUARTERLY REPORT
2025-11-12

TXMD filed its Form 10-Q quarterly report on November 12, 2025. While the filing includes a section dedicated to risk factors under Item 1A, no specific financial highlights or detailed risk disclosures were provided in the available excerpts.

DEF 14A
PROXY STATEMENT
2025-11-03

TXMD filed a definitive proxy statement on November 3, 2025, providing shareholders with the necessary information to vote on corporate matters at an upcoming meeting.

10-Q
QUARTERLY REPORT
2025-08-12

TXMD filed its quarterly report on August 12, 2025. While specific financial highlights were not provided in the excerpt, the filing includes a dedicated section on risk factors under Item 1A.

8-K
CURRENT REPORT
2025-08-12
10-Q
QUARTERLY REPORT
2025-05-13

TXMD filed its quarterly report on May 13, 2025. While specific financial metrics were not provided in the excerpt, the filing includes a dedicated section on risk factors under Item 1A.

8-K
CURRENT REPORT
2025-05-13
8-K
CURRENT REPORT
2025-04-09
10-K
ANNUAL REPORT
2025-03-27
8-K
CURRENT REPORT
2025-03-27
8-K
CURRENT REPORT
2024-12-05
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning TXMD from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile